Bristol Myers Squibb’s Opdivo and Yervoy combination shows unprecedented 10-year survival benefits in advanced melanoma
Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term survival benefits of the Opdivo (nivolumab) and ... Read More
Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection
The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, ... Read More
Everest Medicines launches clinical trial for personalized mRNA cancer vaccine EVM16
Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative personalized mRNA cancer vaccine, EVM16. The trial, ... Read More
Kineta Inc. resumes VISTA-101 trial enrollment for KVA12123 in advanced solid tumors
Kineta Inc. has announced the resumption of patient enrollment in its VISTA-101 Phase 1/2 clinical trial, which is evaluating the efficacy of KVA12123 in treating ... Read More
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More
Agenus announces promising trial results for colon cancer treatment at ESMO Congress
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled promising results from an investigator-sponsored trial (IST) ... Read More
Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics
Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also ... Read More
Cancer immunotherapy company EpicentRx raises $35m in Series D round
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of ... Read More
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference
MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy ... Read More